DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
SEATTLE, Feb. 27, 2018 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual ROTH Conference on Tuesday March 13th, 2018 at 12:00 p.m. PT at the Ritz Carlton, Laguna Niguel, California.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer or autoimmune diseases. Aptevo has two ADAPTIR antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, please visit www.aptevotherapeutics.com
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
[email protected]
